Mivacron (Mivacurium Chloride)

Mivacron is a short‑acting neuromuscular blocker used in anesthesia to achieve rapid muscle relaxation.

• Facilitation of endotracheal intubation: provides brief skeletal muscle relaxation allowing safe tube placement.
• Muscle relaxation during surgery: enables controlled relaxation of skeletal muscles throughout operative procedures.
• Diagnostic procedures requiring short‑acting blockade: allows temporary paralysis for specific investigations such as electromyography.

• Mivacurium acts as a competitive antagonist at nicotinic acetylcholine receptors on the motor end‑plate of skeletal muscle. By occupying the receptor without activating it, the drug blocks acetylcholine‑mediated depolarization, halting nerve‑muscle transmission and producing rapid, short‑lasting skeletal muscle paralysis. Plasma cholinesterase hydrolyzes the molecule, terminating its effect.

Mivacron may be associated with several adverse reactions, ranging from frequent, mild events to rare, serious conditions.

Common Side Effects

• Flushing: transient redness of the skin, often on the face or neck.
• Bronchospasm: narrowing of the airways causing wheezing.
• Hypotension: temporary drop in blood pressure.
• Nausea: feeling of sickness or urge to vomit.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction that can be life‑threatening.
• Prolonged apnea: extended inability to breathe requiring ventilatory support.
• Cardiac arrhythmia: abnormal heart rhythm that may be dangerous.

When using Mivacron, clinicians should observe specific precautions to minimize risk and ensure optimal drug performance.

• Renal impairment: monitor for prolonged neuromuscular blockade as clearance may be reduced.
• Hepatic disease: consider possible extension of drug effect due to altered plasma cholinesterase activity.
• Known hypersensitivity: avoid administration in patients with documented allergy to mivacurium or related compounds.
• Concurrent cholinesterase inhibitors: may prolong paralysis; adjust monitoring accordingly.
• Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mivacron can interact with other agents that affect neuromuscular transmission or cardiovascular stability.

Major Interactions (Avoid)

• Cholinesterase inhibitors (e.g., neostigmine, pyridostigmine): may significantly prolong neuromuscular blockade.
• Aminoglycoside antibiotics (e.g., gentamicin, streptomycin): potentiate muscle relaxation and increase risk of respiratory failure.
• Magnesium sulfate: enhances the blocking effect and can lead to profound paralysis.

Moderate Interactions (Monitor Closely)

• Inhalational anesthetics (e.g., sevoflurane, desflurane): additive muscle relaxation may extend duration.
• Volatile anesthetics: may increase the intensity of blockade, requiring dose adjustment.
• Beta‑adrenergic blockers: can affect hemodynamic response during induction.